Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Kapetanovic, Meliha C ^a   Kristensen, Lars Erik ^a   Saxne, Tore ^a   Aktas, Teodora ^b   Mörner, Andreas ^b   Geborek, Pierre ^a  

^a LUND UNIVERSITY   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; INFLUENZA VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; CONTROLLED STUDY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORNING STIFFNESS; MYALGIA; PANDEMIC INFLUENZA; RHEUMATOID ARTHRITIS; SEASONAL INFLUENZA; SEROCONVERSION; SPONDYLOARTHROPATHY; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VERY ELDERLY; YOUNG ADULT; ANTIBODY PRODUCTION; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; SPONDYLARTHROPATHIES;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SPONDYLARTHROPATHIES; YOUNG ADULT;

EID: 84892522544     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4427     Document Type: Article

References (30)

1. The Influenza A(H1N1) 2009 Pandemic in Sweden, 2009-2010. A Report from the Swedish WHO National Influenza Centre. Available at: http://www.folkhalsomyndigheten.se/pagefiles/12852/the-influenza-a-h1n1-2009-pandemic-in-sweden-2009-2010.pdf.
2. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010, 51:668-677. 10.1086/655830, 20687838.
3. Broadbent AJ, Subbarao K. Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Curr Opin Virol 2011, 1:254-262. 10.1016/j.coviro.2011.08.002, 3224079, 22125588.
4. Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina MJ, Nguyen-Van-Tam JS, Read RC, Warren FC, Zambon M. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011, 11:91-101. 10.1016/S1473-3099(10)70296-6, 21168369.
5. Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, Brady RC, Edupuganti S, Winokur P, Mulligan MJ, Keyserling HL, Kotloff KL, Rouphael N, Noah DL, Hill H, Wolff MC. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis 2012, 206:811-820. 10.1093/infdis/jis427, 3501151, 22782949.
6. Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012, 205:733-744. 10.1093/infdis/jir641, 22315336.
7. Ikematsu H, Tenjinbaru K, Li P, Madan A, Vaughn D. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. Hum Vaccin Immunother 2012, 8:1119-1125. 10.4161/hv.21081, 3551884, 22854661.
8. Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Li P, Walravens K, Gillard P, Roman F. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Hum Vaccin Immunother 2012, 8:260-266. 10.4161/hv.18469, 3367709, 22426369.
9. Swedish National Board of Health and Welfare (Socialstyrelsen) Rekommendationer för vaccination mot den nya pandemiska influensan A(H1N1) 2009. (Recommendation for vaccination against novel pandemic influenza A (H1N1) 2009. Available at: http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18398/2011-8-4.pdf, Swedish National Board of Health and Welfare (Socialstyrelsen).
10. Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, Guillevin L, Villiger PM. Protective effect of A/H1N1 vaccination in immune-mediated disease-a prospectively controlled vaccination study. Rheumatology (Oxford) 2012, 51:695-700. 10.1093/rheumatology/ker389, 22171015.
11. França IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein-Schainberg C, Laurindo IM, Precioso AR, Ishida MA, Sartori AM, Silva CA, Bonfa E. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford) 2012, 51:2091-2098. 10.1093/rheumatology/kes202, 22908326.
12. Iwamoto M, Homma S, Onishi S, Kamata Y, Nagatani K, Yamagata Z, Minota S. Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol Int 2012, 32:3691-3694. 10.1007/s00296-011-2118-1, 21881985.
13. Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, Grillet S, Seebach JD, Kaiser L, Wunderli W, Guerne PA, Siegrist CA. H1N1 Study Group Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011, 63:1486-1496. 10.1002/art.30325, 21384334, H1N1 Study Group.
14. Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, Arad U, Brill A, Paran D, Levartovsky D, Wigler I, Caspi D, Mandelboim M. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011, 63:1062-1067. 10.1002/acr.20465, 21425247.
15. Aikawa N, Campos L, Goldenstein-Schainberg C, Saad C, Ribeiro A, Bueno C, Precioso A, Timenetsky M, Silva C, Bonfá E. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2013, 42:34-40. 10.3109/03009742.2012.709272, 22992045.
16. Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, Duarte A, Miraglia JL, Timenetsky Mdo C, Viana VS, França IL, Bonfa E. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2012, 39:167-173. 10.3899/jrheum.110721, 22089462.
17. Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ET, Sullivan KE. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 2013, 33:388-396. 10.1007/s10875-012-9813-x, 23064976.
18. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81. 10.1002/art.25033, 20039396.
19. Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, Bonfa E. Abatacept severely reduces the immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013, 65:476-480. 10.1002/acr.21838, 22949223.
20. Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012, 71:2006-2010. 10.1136/annrheumdis-2012-201950, 3595981, 22887851.
21. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007, 46:608-611.
22. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011, 63:3723-3732. 10.1002/art.30580, 21834061.
23. Crnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther 2013, 15:R1. 10.1186/ar4127, 3672713, 23286772.
24. De Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol 2003, 115:63-73.
25. Committee for Human Medicinal Products Note for guidance on harmonization of requirements for influenza vaccines. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500007567.pdf, Committee for Human Medicinal Products.
26. Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009, 22:1041-1050. 10.1111/j.1432-2277.2009.00927.x, 19624493.
27. Skowronski DM. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?. J Infect Dis 2008, 197:490-502. 10.1086/524146, 18275271.
28. St Clair EW. Good and bad memories following rituximab therapy. Arthritis Rheum 2010, 62:1-5.
29. Roseman C, Truedsson L, Kapetanovic MC. The effect of smoking and alcohol consumption on markers of systemic inflammation, immunoglobulin levels and immune response following pneumococcal vaccination in patients with arthritis. Arthritis Res Ther 2012, 14:R170. 10.1186/ar3923, 3580564, 22824238.
30. Durier C, Desaint C, Lucht F, Girard PM, Lévy Y, May T, Michelet C, Rami A, Roman F, Delfraissy JF, Aboulker JP, Launay O. ANRS 151 study group and the REIVAC network AIDS: long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults. AIDS 2013, 27:87-93. 10.1097/QAD.0b013e328359f27a, 23018437, ANRS 151 study group and the REIVAC network.